Despite its advantages over other vaccine technologies for Covid-19, adenovirus vector vaccines are likely to be tripped up by pre-existing antibodies to the vectors used and the need for a second injection to boost protection.
CanSino Biologics’ Ad5-nCoV and Johnson & Johnson’s AdVac platform-based vaccine use a human adenovirus vector, but a significant chunk of people may already have neutralising antibodies against the vector, decreasing efficacy prospects. Phase I Ad5-nCoV data is also underwhelming, adding credence to the issue of pre-existing antibodies.
AstraZeneca’s AZD1222 and Rome-based ReiThera’s Covid-19 vaccines are also adenovirus vectored but use nonhuman vectors. However, AZD1222’s recent animal data also leave questions about its utility to prevent virus spread. A possible way to improve efficacy is to add a booster shot down the line, perhaps using a different adenovirus vector or even a different vaccine technology. Perhaps AZD1222 only carrying SARS-CoV-2’s spike protein may not be enough.
There are at least 38 companies or universities with a recombinant adenovirus-derived vaccine asset for Covid-19 from preclinical to Phase II/III stages, according to GlobalData. AstraZeneca partnered with Oxford University on 30 April to further develop AZD1222, and on 3 June, the US Federal Government’s vaccine initiative, Operation Warp Speed, named it as one of five finalists along with Johnson & Johnson’s (J&J) candidate. Phase I/II AZD1222 trial (NCT04324606) data are expected shortly, while J&J’s Phase I/IIa will start in July. ReiThera will also begin a clinical investigation in the summer. CanSino is the only company that has released clinical trial data, with Ad5-nCoV already in a Phase II trial (NCT04341389) that has a primary completion date of January 2021.
AZD1222 is concurrently in Phase II/III trial (NCT04400838), with data timelines dependent on community viral transmission rates, the Oxford University website states. A registrational field trial expected to start in the summer is likely to require around 25,000–30,000 volunteers if the annualised incidence rate is 1.5%, this news service reported on 14 May. While a challenge trial design could be considered to quickly gather protection data, such a trial design also has its own operational and ethical issues.
Image Credit: Envato/ Amanda Scott
News This Week
It is the question scientists around the world are trying to answer: how long can the coronavirus survive in the tiny aerosol particles we exhale? In a high-security lab near Bristol, entered through a series [...]
As the COVID-19 pandemic rages on, researchers are working overtime to develop vaccines and therapies to thwart SARS-CoV-2, the virus responsible for the disease Many efforts focus on the coronavirus spike protein, which binds the [...]
A research team in Hungary pinched the coronavirus with a fine needle to measure how much force it could take before popping like a balloon. It did not. The native virion of Sars-CoV-2 – a [...]
Headaches, confusion and delirium experienced by some Covid-19 patients could be the result of the coronavirus directly invading the brain, according to a study published Wednesday. The research is still preliminary – but offers several [...]
By Boris M | Published in Coronavirus During the COVID-19 pandemic, there will be a lot of information about the virus and its effects on mental health. That’s because coronavirus and the social, financial and psychological [...]
A serious illness suffered by an Oxford University coronavirus vaccine trial participant was most likely “life-threatening”, a bioethics researcher says. But that doesn’t mean the clinical trials will be scrapped. AstraZeneca and Oxford University [...]
Analysis of seven trials finds dexamethasone and hydrocortisone should be given in severe cases. Studies around the world have confirmed that steroids can save lives in the Covid-19 pandemic, leading to new recommendations from [...]
Experts say strong evidence of efficacy needed to avoid approval of inferior vaccines. The rush to immunise populations against Covid-19 could lead to the rollout of a vaccine that is not very effective and [...]
The COVID-19 pandemic has dominated the news cycle for the better part of 2020. As guidelines are continually updated to reflect changes in our understanding of how the virus spreads, it is critical people [...]
Scientists in Hong Kong have reported the first confirmed case of reinfection with the coronavirus that causes Covid-19, reportedly backed up by genetic sequences of the two episodes of the 33-year-old man’s infections in March and [...]
Could uncomfortable nasal swabs be swapped for a contactless two-second breathalyzer puff to check for Covid-19 infection? Prof. Hossam Haick thinks so. Haick, a professor of chemical engineering and nanotechnology at the Technion – [...]
The relationship between antibodies for the novel coronavirus (SARS-CoV-2) and immunity, vaccine efficacy, and spread of COVID-19 has received significant attention. Dr. Seheult is back to illustrate why T cells have received less [...]
Images Description Three individuals were admitted to the hospital (ages 46–56; to men and one woman) with a multiday history of symptoms associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and underwent [...]